Skip to main content

Table 3 Outcome stratified by baseline HbA1c level

From: The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus

  Insulin OHA P value*(95% CI)
HbA1c > 7.0 g/dl N = 111 N = 40  
  Baseline BCVA (approxETDRS letters) 64.88 (12.14) 63.05 (14.42) 0.476 (-3.27, 6.94)
  Final BCVA (approxETDRS letters) 69.76 (9.51) 65.68 (16.48) 0.145 (-1.46, 9.62)
  BCVA change (approxETDRS letters) 4.87 (10.11) 2.63 (12.75) 0.434 (-1.00, 5.00)
  Baseline CMT (microns) 386.16 (109.14) 393.25 (119.46) 0.743 (-50.12, 35.95)
  Final CMT (microns) 319.37 (69.67) 315.05 (84.72) 0.774 (-25.57, 34.21)
  CMT change (microns) -66.78 (107.51) -78.20 (123.30) 0.704 (-24.00, 34.99)
  Injection number 8.27 (3.08) 7.60 (3.22) 0.259 (-0.50, 1.84)
HbA1c ≤ 7.0 g/dl N = 26 N = 21  
  Baseline BCVA (approxETDRS letters) 60.65 (15.95) 66.00 (8.06) 0.145 (-12.61, 1.91)
  Final BCVA (approxETDRS letters) 62.23 (20.70) 66.57 (13.60) 0.393 (-14.48, 5.80)
  BCVA change (approxETDRS letters) 1.58 (15.14) 0.57 (8.97) 0.845 (-5.00, 5.00)
  Baseline CMT (microns) 355.42 (53.72) 403.10 (104.55) 0.068 (-99.11, 3.77)
  Final CMT (microns) 316.88 (66.58) 337.38 (95.82) 0.411 (-70.57, 29.58)
  CMT change (microns) -38.54 (72.18) -65.71 (124.70) 0.391 (-26.99, 89.99)
  Injection number 8.19 (2.91) 8.76 (3.28) 0.538 (-2.42, 1.28)
  1. Abbreviations: BCVA Best corrected visual acuity, CMT Central macular thickness, CI Confidence interval, approxETDRS Approximate early treatment diabetic retinopathy study, OHA Oral hypoglycemic agent
  2. Data are presented as means ± SD. N represents the total case number (percentage) in each group. *p-values are for a difference between insulin and OHA group. 95% CI is for the difference between the means of the two groups. Independent t-test/Mann–Whitney U test for continuous variables between treatment groups; Significant p-values are in bold